Transforming growth factor ␤ (TGF-␤) pathways are key determinants of cell fate in animals. Their basic mechanism of action is simple. However, to produce cell-specific responses, TGF-␤ pathways are heavily regulated by secondary factors, such as membrane-associated EGF-CFC family proteins. Cellular activities of EGF-CFC proteins have been described, but their molecular functions, including how the mammalian homologs Cripto-1 and Cryptic recognize and regulate TGF-␤ family ligands, are less clear. Here we use purified human Cripto-1 and mouse Cryptic produced in mammalian cells to show that these two EGF-CFC homologs have distinct, highly specific ligand binding activities. Cripto-1 interacts with BMP-4 in addition to its known partner Nodal, whereas Cryptic interacts only with Activin B. These interactions depend on the integrity of the protein, as truncated or deglycosylated Cripto-1 lacked BMP-4 binding activity. Significantly, Cripto-1 and Cryptic blocked binding of their cognate ligands to type I and type II TGF-␤ receptors, indicating that Cripto-1 and Cryptic contact ligands at their receptor interaction surfaces and, thus, that they could inhibit their ligands. Indeed, soluble Cripto-1 and Cryptic inhibited ligand signaling in various cell-based assays, including SMAD-mediated luciferase reporter gene expression, and differentiation of a multipotent stem cell line. But in agreement with previous work, the membrane bound form of Cripto-1 potentiated signaling, revealing a critical role of membrane association for its established cellular activity. Thus, our studies provide new insights into the mechanism of ligand recognition by this enigmatic family of membrane-anchored TGF-␤ family signaling regulators and link membrane association with their signal potentiating activities.
The mammalian "epidermal growth factor-Cripto/FRL-1/ Cryptic" (EGF-CFC) 2 family proteins Cripto-1 and Cryptic are membrane-anchored regulators of TGF-␤ family signaling that have key roles in early embryonic development (1) (2) (3) (4) (5) (6) . Cripto-1 (also known as TDGF1) is a marker of stem cell pluripotency that is implicated in embryonic patterning (7) (8) (9) (10) (11) . Cryptic (also known as CFC1) is associated with heart morphogenesis and left-right asymmetry specification (12) (13) (14) . Biological functions beyond embryogenesis are not known, but both play major roles in human diseases. Cripto-1 is associated with colon, breast, pancreatic, ovarian, lung, and other cancers (15) (16) (17) (18) . Cryptic is associated with heterotaxy syndromes and other laterality defects (19 -21) .
Molecular genetic studies have established a functional link between Cripto-1 and the TGF-␤ family ligand Nodal (4, 22) : Nodal co-immunoprecipitated with Cripto-1 and required Cripto-1 for signaling (9, 13, (23) (24) (25) (26) (27) (28) (29) . These findings have supported the idea that Cripto-1 and the EGF-CFC family are obligate Nodal "co-receptors" that potentiate Nodal signaling (3, 30, 31) . However, the fundamental requirement of Cripto-1 for this function is not certain, as some studies indicated that Nodal can bind its receptors and can have signaling activities without Cripto-1 (8, 25-27, 32, 33) . Intriguingly, a number of studies discovered a seemingly contradicting function. Namely, Cripto-1 blocked signaling by the TGF-␤ family ligands Activin A, Activin B, and TGF-␤1, indicating Cripto-1 could also act as antagonist of some ligands (28, 34 -36) . Together, these findings indicate that the function of Cripto-1 remains unclear. Although Cripto-1 has been widely investigated, less is known about Cryptic, except that it is also implicated in Nodal signaling (13, 29, 30) .
To clarify the functions of Cripto-1 and Cryptic, we examined their molecular mechanisms in TGF-␤ family signaling. Using purified proteins expressed in mammalian cells and protein-protein interaction analysis, we showed human Cripto-1 binds Nodal as expected, but not Activin A or Activin B as previously suggested. Notably, we discovered Cripto-1 also binds BMP-4 with high affinity, revealing a new regulatory function. By contrast, mouse Cryptic only bound Activin B, indicating its biological activities are different from Cripto-1.
We also investigated how Cripto-1 and Cryptic recognize ligands. Using a surface plasmon resonance competition assay (37) , we discovered both Cripto-1 and Cryptic inhibited ligandreceptor binding, indicating they contact the type I and type II receptor recognition surfaces on ligands (38) . As both Cripto-1 and Cryptic blocked ligand-receptor binding, we speculated they could inhibit signaling. Using reporter gene expression assays, and an extraembryonic endoderm stem (XEN) cell differentiation assay (39, 40) , we demonstrated that soluble forms of Cripto-1 and Cryptic, respectively, inhibited BMP-4 and Activin B signaling in a cellular context. But in agreement with earlier reports on the role of Cripto-1 in Nodal function, membrane-bound Cripto-1 potentiated BMP-4 signaling. This finding reveals a potentially critical role for membrane association in signal potentiation. In summary, we provide a molecular framework that helps explain the function of these enigmatic TGF-␤ family signaling regulators. Although soluble Cripto-1 and Cryptic can act as inhibitors, membrane-anchored forms could exploit this ligand capture function and localize ligands to endosomal vesicles as a way to potentiate signaling (41, 42) .
Results
Production of Soluble Cripto-1 and Cryptic-A critical bottleneck in the molecular analysis of mammalian Cripto-1 and Cryptic has been the lack of purified, active proteins. Several complicating factors contribute to this problem. Both Cripto-1 and Cryptic are expressed as secreted precursors that attach to the membrane via a glycosylphosphatidylinositol (GPI) anchor, both have six disulfide bonds distributed between two separate domains, and both may require post-translational fucosylation for biological activity (5, (43) (44) (45) . To obtain active Cripto-1 and Cryptic we used stably transfected Chinese hamster ovary (CHO) cells, as they can carry out the required post-translational modifications. We created a Cripto-1 expression construct that included the Cryptic signal peptide and human Cripto-1 extracellular (ecto)-domain amino acids . We also created a mouse Cryptic expression construct that included the native signal peptide plus ectodomain amino acids 36 -175 ( Fig. 1A ). Both fragments were fused at their C terminus, which is near the predicted GPI processing site, to human IgG1 Fc (Fig. 1, A and B) . Fusion proteins were purified from conditioned medium by protein A affinity capture. A size exclusion chromatography (SEC) step was further required to remove inactive aggregates (Fig. 1C ). Overall, we obtained approximately ϳ100 mg of highly purified hCripto-1-Fc and ϳ50 mg of mCryptic-Fc/liter of culture. Notably, the C terminus was critical for expression, as constructs that ended near the C-terminal cysteine were highly aggregated, and constructs that ended at the putative GPI processing site failed to secrete.
Cripto-1 and Cryptic Bind Distinct Ligands-Genetic and coimmunoprecipitation studies have indicated that Cripto-1 and Cryptic interact with the TGF-␤ family ligands Nodal and Activin A (9, 13, 28, 35) . Using SPR we confirmed earlier that Cripto-1 binds Nodal with high affinity (33), but we did not detect Activin A binding to Cripto-1 or Nodal binding to Cryptic. These findings indicated that previously proposed ligandbinding and regulatory activities of Cripto-1 and Cryptic are inaccurate. To identify ligands that interact directly with (and thus are regulated by) Cripto-1 or Cryptic, we used a highthroughput, SPR-based binding assay. We captured purified human Cripto-1-Fc or mouse Cryptic-Fc on an SPR sensor chip cross-linked with an anti-Fc antibody and injected 17 different TGF-␤ family ligands at an 80 nM concentration (Fig. 2, A and  B) . Cripto-1-Fc bound Nodal and, to a lesser degree GDF-3, but not Activin A, as had been proposed. Notably, we discovered that Cripto-1-Fc interacts very strongly with BMP-4 ( Fig. 2A) . By contrast, mouse Cryptic-Fc did not bind Nodal, Activin A, BMP-4, or GDF-3, but interacted very specifically and strongly with Activin B (Fig. 2B ). We did not observe appreciable binding of any other tested TGF-␤ family ligand to either Cripto-1 or Cryptic, including TGF-␤1, TGF-␤2, TGF-␤3, GDF-8, GDF-11, GDF-15, BMP-2, BMP-3, BMP-6, BMP-7, BMP-9, or BMP-10. We confirmed our single injection findings with systematic ligand titrations and obtained kinetic rate and equilibrium binding constants for BMP-4, GDF-3, and Activin B (Fig. 2 , C-F, Table 1 ). To determine whether the Fc moiety affects ligand binding, we cross-linked Fc-free Cripto-1 directly on the sensor chip. Notably, Cripto-1 captured in this way bound BMP-4 with ϳ40-fold lower affinity, indicating that the Fc moiety or the capture method impact ligand binding (Fig. 2 , C and D). We speculate three factors could contribute to the difference in affinity: 1) a loss of avidity due to use of the Fc-free, monomeric form; 2) a loss in binding activity due to chemical modification of lysine residues on Cripto-1; and/or 3) a gradual loss in binding activity caused by repeated regeneration of the Cripto-1 bound surface. Despite the observed differences in binding rates, our findings show that Cripto-1 binds BMP-4 with high affinity regardless of capture method. In conclusion, we have identified two new TGF-␤ family ligands that are bound (and thus regulated) by Cripto-1 or Cryptic, namely BMP-4 and Activin B. Importantly, we show Cripto-1 and Cryptic interact with different ligands, indicating they have markedly distinct biological functions.
All Cripto-1 Domains Are Required for Ligand Binding-EGF-CFC family proteins comprise three structural domains, an N-terminal low homology region (N), an epidermal growth factor (E)-like motif, and a C-terminal Cripto-FRL1-Cryptic (C) domain (Fig. 1A) . The molecular functions of individual domains have been investigated, but results are inconclusive. For example, some studies indicate the EGF domain is required for signaling, whereas others suggest it is not (26, 30) . Some indicate the EGF domain binds Nodal, whereas others indicate it does not (30, 42, 46) . Some suggest the CFC domain interacts with ALK4, whereas others indicate it may not (26, 30) . To clarify the contribution of Cripto-1 domains in ligand interactions, we created constructs that consisted of two domains (NE, EC, and NC) or single domains (N, E, or C) and compared their ability to bind ligands with that of full-length Cripto-1-Fc (NEC). We expressed and purified the six domain deletion constructs as described for the full-length form, and tested their ability to bind BMP-4 using single injection SPR binding. Of the six constructs, five were readily expressed and purified. The N-terminal domain construct (N) was severely degraded and thus was not used in these studies. Both two-domain constructs that included the EGF region (NE and EC) bound BMP-4, although binding was significantly weaker compared with full-length Cripto-1-Fc ( Fig. 2G ). Single domain constructs did not bind BMP-4. Taken together, these findings indicate that all three Cripto-1 domains are required for the BMP-4 interaction. However, whether all three domains contact BMP-4 directly or whether they help support a Cripto-1 conformation that recognizes BMP-4, remains to be determined. We did not test Cripto-1 domain functions against Nodal, as we do not have consistently active Nodal ( Fig. 2A ). But we expect Nodal to parallel our BMP-4 findings.
Cripto-1 Glycosylation Is Necessary for Ligand Binding-Human Cripto-1 is glycosylated at asparagine 79. This glycosylation site appears to be conserved across all mammalian species (Fig. 1A) , indicating the glycan moiety may have functional relevance. To determine whether Asn-79 glycosylation has a role in ligand binding, we enzymatically processed Cripto-1 with the endoglycosidases PNGase F or ENDO-F3. PNGase F removes the entire glycan. ENDO-F3 leaves the N-acetylglucosamine moiety on the protein. Strikingly, both PNGase F-and ENDO-F3-treated Cripto-1-Fc lost the ability to bind BMP-4, indicat-ing that Asn-79 glycosylation is critical for Cripto-1 function ( Fig. 2H ). Importantly, this finding supports our conclusion that Cripto-1-ligand recognition requires multiple structural features. However, whether Asn-79 glycosylation is directly involved in ligand binding or whether it plays a structural role remains to be determined. Notably, Asn-79 is at the junction between N and E domains. Only three of our domain constructs, NE, EC, and E, carried this glycosylation site. NE and EC constructs also lose their binding activity after deglycosylation ( Fig. 2H) .
Soluble Cripto-1 Does Not Bind Type I Receptors with High Affinity-The commonly accepted model of Cripto-1 action is that it binds both Nodal and the type I TGF-␤ family receptor ALK4 to stabilize Nodal⅐ALK4 complexes and thus potentiate Nodal signaling (26, 30, 46, 47) . Specifically, it is suggested the EGF domain contacts Nodal and the CFC domain contacts ALK4, thus linking Nodal with its type I receptor and stabilizing an active signaling complex (48, 49) . But our findings show the function of Cripto-1 is more complex. Namely, ligand binding Fc-fusion form constructs were captured from conditioned medium using protein A affinity chromatography and further purified using size exclusion chromatography. Constructs migrate as a single, well defined peak in a size exclusion chromatographic column. The molecular weight of the protein corresponds to the dimeric species. Non-reducing and reducing SDS-PAGE gels show the disulfide-linked dimeric species and the reduced, monomeric species. Dimerization occurs via free a cysteine in the Fc region. 2G ). To investigate the function of Cripto-1 in ligand-receptor complex stabilization, we first examined if Cripto-1 binds TGF-␤ family receptors directly. We captured type I receptors ALK2, ALK3, and ALK4, or type II receptors ActRIIA, ActRIIB, BMPRII, and T␤RII on a sensor chip, as these receptors interact with the cognate Cripto-1/Cryptic ligands Nodal, BMP-4, and Activin B (50) . We injected 6 M Fc free Cripto-1 or Cryptic (Fig. 3A ). Cripto-1 elicited a strong SPR response when injected over ALK4. But the response was dominated by extremely fast on-and off-rates, indicating it is dominated by significant bulk shift or nonspecific binding components (Fig. 3A) . A weaker response with similarly fast kinetics could also be observed with other receptors. In contrast to Cripto-1, Cryptic did not elicit an SPR response with any captured receptors (data not shown).
To identify the source of the SPR response, we evaluated the Cripto-1-ALK4 dose-response relationship. We titrated Fc free Cripto-1 over ALK4 at concentrations ranging from 46 nM to 24 M ( Fig. 3B ). As anticipated from our single injection studies, the SPR response increased with Cripto-1 concentrations. But the SPR response did not follow Langmuir adsorption kinetics ( Fig. 3B ). Thus, we fit our binding data using a "one-site total binding" model and obtained a K d of ϳ750 nM with a maximum specific binding value (B max ) of 62.5 response units (RU) ( Fig.  3B ) (51) . Based on this analysis and the observation that Cripto-1 caused small SPR responses with other tested receptors ( Fig. 3A) , we propose that the Cripto-1-ALK4 interaction is weak, and that Cripto-1 can interact nonspecifically with receptors. Notably, when we injected ALK4 over captured Cripto-1, we observed a similar response dominated by bulk shift and kinetic rate constants (data not shown).
Earlier studies indicated the CFC domain interacts directly with ALK4 (52). To assess this observation, we captured domain deletion constructs on a sensor chip and injected 24 M ALK4. We hypothesized that constructs, which include the CFC domain, bind ALK4, but constructs that lack the CFC . Equilibrium binding analysis does not fit a standard Langmuir model. Instead, nonlinear curve fitting using a "one-site total binding" model was used (inset, solid line, circles). B max, K d , and nonspecific contribution were determined. The theoretically determined nonspecific contribution is also shown (inset, dotted line, triangles). C, binding of ALK4 to Cripto-1 domain deletion constructs. Deletion constructs were captured on the sensor chip and 6 M Fc free ALK4 was injected. Constructs and corresponding binding curves are color-matched. D, glutaraldehyde cross-linking of Cripto-1 and ALK4. The SDS-PAGE gel shows Cripto-1, ALK4, cross-linked (XL) Cripto-1, cross-linked ALK4, and cross-linked complexes. 0.01% (left lane) and 0.02% (right lane) glutaraldehyde was used. Molecular weight markers are shown on the left side. E, binding of Nodal Ϯ Cripto-1 to Nodal receptors ActRIIA (blue), ActRIIB (red), and ALK4 (green). The minus sign denotes curves obtained with Nodal only (thick, light colored lines), the plus sign denotes curves obtained with Nodal preincubated with Cripto-1 (thin, dark colored lines). A Cripto-1 injection over captured ALK4 was subtracted from the Nodal⅐Cripto-1 injection over captured ALK4 to eliminate the nonspecific Cripto-1⅐ALK4 binding contribution. F, binding of Nodal Ϯ ALK4 (green) to Cripto-1. The presence of ligand does not appear to alter the SPR signal obtained for Cripto-1 and ALK4 significantly.
domain do not. As anticipated, we observed an SPR response with all CFC domain constructs, but not with constructs lacking this domain ( Fig. 3C ). However, responses were again dominated by bulk shift, indicating the interaction is weak and has significantnonspecificelements.Toobtainanindependentmeasure of Cripto-1⅐ALK4 binding, we used glutaraldehyde crosslinking and SDS-PAGE. We hypothesized that a cross-linking product would show Cripto-1⅐ALK4 complexes are stable. But we failed to detect adducts using this approach (Fig. 3D ).
To determine whether ligands help stabilize Cripto-1⅐ALK4 or other Cripto-1⅐receptor complexes, we performed two independent SPR experiments. First, we captured ALK4-Fc, ActRIIA-Fc, or ActRIIB-Fc on the sensor chip and injected Nodal or Nodal preincubated with Fc-free Cripto-1 ( Fig. 3E ). Strikingly, whereas Cripto-1 did not have a noticeable effect on the weak Nodal-ALK4 interaction, indicating Cripto-1 does not stabilize Nodal⅐ALK4 complexes in this format ( Fig. 3E ), Cripto-1 prevented binding of Nodal to the type II receptors ActRIIA and ActRIIB. In a second experiment, we captured Cripto-1-Fc and injected Nodal alone or Nodal preincubated with ALK4 ( Fig. 3F ). ALK4 did not enhance Cripto-1⅐Nodal complexation. We therefore conclude that Cripto-1⅐ALK4 complexes are weak and that a direct interaction between these two proteins may not be very consequential.
Cripto-1 and Cryptic Block Ligand Association with Type II and Some Type I Receptors-It is well established that Cripto-1 and Cryptic interact with TGF-␤ family ligands (9, 26, 33, 34) , but how they bind ligands is not clear. Based on molecular knowledge about the TGF-␤ family ligand-receptor interaction (38) , we hypothesized Cripto-1 and Cryptic either contact ligand surfaces that overlap with receptor binding sites (and thus compete with receptors for ligand binding), or they contact ligand surfaces that do not overlap with receptor binding sites (and thus form multimeric complexes with ligands and receptors, as is suggested). To test this hypothesis, we used an SPR-based co-binding/inhibition assay (37) . In this format, receptor-Fc fusion constructs were captured on the sensor chip and a constant concentration of ligand preincubated with increasing concentrations of Cripto-1 or Cryptic was injected. If Cripto1/Cryptic and receptors occupy the same ligand surface, the SPR signal is expected to decrease with increasing Cripto-1/Cryptic concentrations. But, if Cripto1/Cryptic and receptors occupy different ligand surfaces, the SPR signal is expected to increase with increasing Cripto-1/Cryptic concentrations (37) .
Using this approach, we discovered that soluble Cripto-1 prevents BMP-4 binding to type I receptor ALK3 and type II receptors ActRIIA and BMPRII in a concentration-dependent manner (Fig. 4 , A-C), replicating our observation with Nodal (Fig. 3E) . The reaction followed a sigmoidal inhibition curve (Fig. 4D) , indicating Cripto-1 competitively inhibited BMP-4 binding to its receptors. Based on the changing SPR response (37), we calculated IC 50 values for inhibition of BMP-4 binding to ActRIIA (705 nM), BMPRII (173 nM), and ALK3 (288 nM) ( Table 2 ). Soluble Cryptic showed a similar behavior (Fig. 5, A  and B) . But the effect of Cryptic on Activin B was more discriminatory, as Cryptic-Fc blocked Activin B binding to the type II receptor BMPRII much more effectively than to ActRIIA (Fig.  5C ). We calculated IC 50 values for inhibition of Activin B binding to BMPRII (288 nM) and ActRIIA (1024 nM) ( Table 2 ). We did not investigate the function of Cryptic in the Activin B-type I receptor interaction, as high affinity type I receptors for Activin B are not known. Significantly, Cripto-1 also prevented Nodal binding to type II receptors (Fig. 3E ), but these findings are preliminary, as the activity of currently available Nodal is not consistent. Even so, our studies support the conclusion that Cripto-1 and Cryptic contact ligands at or near their type I and type II receptor binding sites.
Soluble Cripto-1 and Cryptic Inhibit Signaling-As Cripto-1 and Cryptic inhibited ligand-receptor binding, we hypothesized they could also inhibit ligand signaling. To test this hypothesis, we used reporter gene expression assays. We transfected HepG2 hepatocellular carcinoma cells with control plasmid pGL4.74 (hRluc) and the SMAD-3 responsive reporter plasmid pGL4.48 (luc2P/SBE) or the SMAD-1/5/8 responsive reporter plasmid pGL3 (luc2P/BRE) ( Fig. 6) (53, 54) . We treated transfected cells with 1 nM BMP-4 or Activin B and increasing concentrations of Cripto-1-Fc or Cryptic-Fc (0 -5000 nM). Both ligands induced luciferase reporter activity and both Cripto-1-Fc and Cryptic-Fc reduced the luciferase signal in a concen-tration-dependent manner. Cripto-1-Fc abrogated the BMP-4mediated SMAD-1/5/8 response completely (Fig. 6A, Table 9 3). Cryptic-Fc exhibited an intriguing behavior. It blocked Activin B-mediated SMAD-1/5/8 signaling completely. But inhibition followed a biphasic dose-response ( Fig. 6C ), indicating it blocks at least two distinct Activin B signaling complexes with different potency. Notably, Cryptic-Fc inhibited the Activin B-induced SMAD-2/3 signal only by about half (Fig. 6D) , indicating signaling may be activated differentially by type II receptors. As indicated by our SPR data (Fig. 5 ), Cryptic-Fc may block activation by one receptor (BMPRII) much more effectively than by others (ActRIIA, ActRIIB).
To validate Cripto-1 domain functions, we also evaluated their inhibitory potency (Fig. 6B ). We treated transfected HepG2 cells with 1 nM BMP-4 and 1000 nM Cripto-1-Fc domain constructs. Matching our SPR results (Fig. 2G) , only full-length Cripto-1-Fc (NEC-Fc) exhibited full inhibitory potency (a 5-fold reduction in signaling from 30 to 6 Renilla luciferase units (RLU)). Both two-domain constructs (NE-Fc and EC-Fc) showed residual inhibitory activity, but were far weaker than the full-length construct. They reduced signaling only from 30 to about 20 RLU. Single domains (E-Fc and C-Fc) did not inhibit signaling.
Membrane-associated Cripto-1 Potentiates BMP-4 Signaling-Endogenously expressed, membrane-anchored Cripto-1 is known for its ability to potentiate Nodal signaling (26, 30, 46, 47) . By contrast, we discovered that soluble Cripto-1-Fc inhibits Nodal and BMP-4 signaling ( Figs. 4 -6 ). To reconcile these two opposing activities we examined how endogenously expressed and overexpressed Cripto-1 affect BMP-4 signaling (Fig. 7) . We found that Cripto-1 was efficiently overexpressed in transiently transfected HepG2 cells (Fig. 7, A and B) and strongly knocked down by shRNA in endogenously expressing NT2/D1 cells (Fig. 7C) . Consistent with the potentiating activity of membrane-anchored Cripto-1, BMP-4 signaling was 2-3fold higher in HepG2 cells transfected with Cripto-1 expression vector compared with HepG2 cells transfected with control vector (Fig. 7D ). But Cripto-1 did not potentiate signaling by the BMP-4 homolog BMP-2, which we found does not bind Cripto-1 ( Fig. 2A ). In agreement with our earlier findings, soluble Cripto-1-Fc neutralized the potentiating activity of membrane-associated Cripto-1 in HepG2 cells (Fig. 7E) , revealing key functional differences between soluble and membranebound forms. In support of our findings using HepG2 cells and Cripto-1 overexpression, BMP-4 signaled effectively in NT2/D1 cells transfected with scrambled shRNA vector, whereas Cripto-1 shRNA knockdown strongly suppressed BMP-4 signaling activities (Fig. 7F ). Taken together, our findings indicate that membrane-anchored Cripto-1 can potentiate signaling by its cognate ligands, whereas the soluble form can inhibit signaling and outweigh the activities of the membraneanchored form.
Soluble Cripto-1 Prevents BMP-4-dependent XEN Cell Differentiation-BMP-4 is a key regulator of embryogenesis that promotes differentiation of multipotent XEN cells to extraembryonic visceral endoderm (VE) identity (39, 40) . We hypothesized, if soluble Cripto-1 inhibits BMP-4 signaling, it will interfere with BMP-4-mediated XEN cell differentiation. To test this hypothesis, we examined morphological and gene expression changes of XEN cells cultured in the presence or absence of BMP-4, or BMP-4 and Cripto-1-Fc. As expected, BMP-4 promoted a profound morphological change in XEN cells, reminiscent of the epithelial VE (Fig. 8A , compare untreated with BMP-4-treated panels). In addition, expression of VE markers was strongly induced (Fig. 8B ). However, co-culture with Cripto-1-Fc strongly suppressed both morphological and gene expression changes normally induced by BMP-4 ( Fig.  8, A, compare BMP-4 and BMP-4 ϩ Cripto-1, and B) , indicating that soluble Cripto-1-Fc can interfere with BMP-4-induced differentiation of XEN cells, and thus act as a BMP-4 antagonist in a stem cell model of development.
Discussion
The EGF-CFC family proteins Cripto-1 and Cryptic are essential regulators of TGF-␤ family signaling (2) . They appear to have dual functions: as co-receptors of Nodal-related ligands (3, 30, 31) , and as antagonists of Activins and TGF-␤s (28, 34 -36) . To reconcile these dichotomous activities, we aimed to elucidate their mechanism of action. Using recombinant human Cripto-1 and mouse Cryptic, we discovered both molecules interact with a limited number of TGF-␤ family ligands. Cripto-1 interacted with Nodal and BMP-4, Cryptic interacted with Activin B. Intriguingly, a recent study found that Cripto-1 is expressed at the bottom of colonic crypts in normal human and mouse colon (55), indicating it could regulate signaling of BMP-4 expressed by intravillus and intercrypt mesenchymal cells that are adjacent to intestinal stem cells (56) . It has been suggested that Cripto-1 and Cryptic have similar, possibly redundant functions. But our biophysical evidence indicates there are clear functional differences between the two molecules. Thus, we propose Cripto-1 and Cryptic have distinct, non-overlapping ligand binding and regulatory functions.
Previous studies have indicated that Cripto-1 binds the TGF-␤ family receptor ALK4. This interaction is thought to be critical for Cripto-1 co-receptor function and Nodal signaling (26, 28, 47) . To evaluate its functional significance, we investigated whether Cripto-1 or Cryptic bind ALK4 or other TGF-␤ family receptors directly. Using SPR, we detected a response when probing Cripto-1 binding to ALK4. However, although these results appear to confirm an interaction, they are not conclusive, as the response is dominated by a nonspecific binding component. Significantly, Cripto-1 did not cross-link with ALK4 in solution or improve Nodal⅐ALK4 complexation. We 
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Reporter MARCH 10, 2017 • VOLUME 292 • NUMBER 10 therefore conclude that the direct interaction between soluble Cripto-1 and ALK4 is weak, possibly nonspecific and of limited consequence. However, our findings do not exclude a role for Cripto-1 in ALK4-dependent Nodal signaling. Previously, this interaction was investigated by co-immunoprecipitation (9, 26) . These studies showed Cripto-1 co-precipitated with ALK4. It is possible that the cell-based approach masked a more complex behavior. Namely, Cripto-1⅐ALK4 complexes could have been bridged by ligands that are present in the cell-growth medium. Alternatively, cell-surface proteins like LRP5, LRP6, or glypican could have facilitated Cripto-1⅐ALK4 complexation (57, 58) . Or ALK4 could have contacted the GPI linker, which is not present in Fc fusion forms. Although we show that the direct Cripto-1⅐ALK4 ectodomain interaction is weak and possibly nonspecific, whether Cripto-1 interacts with ALK4 indirectly, and what the function of this complex is, remains to be determined. The most widely recognized function of Cripto-1 is as Nodal co-receptor (2) . It is suggested Cripto-1 binds Nodal and potentiates Nodal signaling by stabilizing Nodal⅐ALK4 complexes (9, 23, 25, 26, 30) . But Cripto-1 also antagonizes Activin and TGF-␤ signaling (28, 35, 36) . To reconcile these divergent functions, we investigated how Cripto-1 and Cryptic recognize ligands. We speculated that molecular knowledge of this interaction could help clarify their biological functions. Using an SPR-based approach that enables binding site mapping (37), we discovered Cripto-1 and Cryptic contact ligand surfaces that are also recognized by type I or type II receptors ( Fig. 9 ). Although unexpected, these findings are not surprising, as ligands are small, and a large fraction of their surface is covered by receptors when they form signaling complexes (38, 59) . As our findings indicated there is significant overlap between the Cripto-1, Cryptic, and receptor binding sites on ligands, we hypothesized that soluble Cripto-1 and Cryptic could function as inhibitors of their cognate ligands in vitro. As predicted, Cripto-1-Fc inhibited BMP-4-dependent reporter gene expression and differentiation of XEN cells to VE, consistent with the observation that VE formation is aberrant in Cripto-1 knockout embryos (8) .
Cripto-1 and Cryptic Ligand-binding Functions and Mechanism
By contrast, Cryptic-Fc inhibited Activin B-dependent reporter gene expression, supporting the conclusion that Cripto-1 and Cryptic have differing activities. Strikingly, the Cryptic-Fc reaction revealed a biphasic dose-response. As Cryptic-Fc was a far more effective inhibitor of Activin B-BM-PRII than Activin B-ActRIIA binding, we propose the biphasic response reflects differential inhibition of BMPRII and ActRIIA signaling complexes in vitro.
Taken together, our biophysical and in vitro studies show Cripto-1 and Cryptic can compete with receptors for ligand binding, thus revealing the molecular basis of their interaction with ligands. As Cripto-1 and Cryptic appear to bind ligands at or near receptor binding sites ( Fig. 9) , it is not surprising that the soluble Fc-fusion forms effectively inhibit signaling by their cognate ligands. But our findings raise critical questions about the co-receptor function. How can Cripto-1 or Cryptic potentiate signaling when their soluble forms prevent ligand-receptor complex formation? We propose that this mechanism has precedent in the repulsive guidance molecule (RGM) family of GPI anchored co-receptors (60 -62) . Like Cripto-1 and Cryptic, membrane-anchored RGMs potentiate BMP signaling, whereas their soluble forms inhibit BMP signaling (63) . Recent crystal structures explain the inhibitory function of RGMs. Similar to Cripto-1 and Cryptic, they occupy type I receptor binding sites on ligands and thus inhibit signaling (64) . To reconcile the RGM co-receptor and inhibitor functions, the authors propose RGMs help target BMP ligands into endosomes (64) , which are enriched with TGF-␤ family receptors (65) . Thus, RGMs could help potentiate signaling. We propose Cripto-1 and Cryptic could have similar trafficking functions, which are mediated by GPI-dependent membrane attachment and endosomal membrane localization (42) . Indeed, overexpression of GPI-anchored Cripto-1 on the cell surface potentiates BMP-4 signaling, whereas knockdown of endogenously expressed Cripto-1 reduces BMP-4 signaling, revealing a distinct, but critical function of the membrane-associated forms. We propose Cripto-1 and Cryptic may provide a mechanism for ligand capture at the cell surface and help target cognate ligands into receptor-rich endosomes for signal potentiation.
In conclusion, we have elucidated the molecular basis of ligand recognition by the EGF-CFC family co-receptors Cripto-1 and Cryptic. Our findings reveal an unexpected molecular function that may be paralleled by the RGM family of GPI-anchored co-receptors. Namely, like RGMs, Cripto-1 and Cryptic contact receptor interaction surfaces on TGF-␤ family ligands. Thus, their soluble forms can function as inhibitors of ligand-receptor binding. But our findings also raise many new questions. Does the inhibitor function have a biological role? Do endocytosis or trafficking explain how membrane-anchored Cripto-1 and Cryptic potentiate signaling (41, 42) ? Can the co-receptor and inhibitor functions be reconciled? 
Materials and Methods
TGF-␤ Family Ligands-Activin A (338-AC/CF), Activin B (659-AB/CF), and TGF-␤1 (240-B/CF) were purchased from R&D Systems or produced in house. Nodal (3218-ND/CF), GDF-1 (6937-GD/CF), GDF-3 (958-G3/CF), GDF-8 (788-G8/ CF), GDF-11 (1958-GD/CF), GDF-15 (957-GD/CF), BMP-4 (314-BP/CF), and BMP-9 (3209-BP/CF) were purchased from R&D Systems. BMP-2 (C-67309), BMP-6 (C-67307), BMP-7 (C-67319), BMP-10 (C-67317), TGF-␤2 (C-63498), and TGF-␤3 (C-63508) were purchased from PROMOCELL. We note that both BMP-4 and GDF-3 lose activity within 8 weeks after reconstitution under the recommended conditions.
Expression Plasmids-Synthetic Cripto-1-hIgg-Fc and cryptic-hIgg-Fc genes were obtained from GeneArt. Full-length fusion constructs included the human Cryptic signal peptide , and the extracellular domains of human Cripto-1 and mouse Cryptic (36 -175) . Functional domains were linked to human IgG1 Fc via a 22-amino acid long linker containing a tobacco etch virus cleavage site, a glycine/serine-rich region, and a FLAG tag. Domain deletion constructs were generated by PCR or were purchased from GeneArt.
Protein Purification-Proteins were expressed using stably transfected Chinese hamster ovary cell pools. The secreted fusion constructs were captured from conditioned medium using Protein A affinity chromatography, eluted with 100 mM glycine, pH 3.0, subjected to SEC, dialyzed into phosphate-buffered saline, pH 7.5, and stored at Ϫ20 or Ϫ80°C. For inhibition assays, the Fc was removed using tobacco etch virus protease followed by protein A affinity chromatography and SEC. Purity was determined with SDS-PAGE.
Cell Lines-CHO cells were obtained from Life Technologies. HepG2 cells (HB-8065) and NTERA2 cl.D1 (NT2/D1) cells (CRL-1973) were obtained from ATCC (American Type Culture Collection) and maintained as indicated by the supplier. Briefly, HepG2 and NT2/D1 cells were grown in Eagle's minimum essential medium supplemented with 10% FBS and 1% penicillin/streptomycin at 37°C in 5% CO 2 and 10% CO 2 , respectively. Cells were passaged at least three times before performing assays. Passage number did not exceed 15. XEN cell lines were cultured as described (66) .
Surface Plasmon Resonance-Binding affinities and inhibition were determined using the Biacore 2000. Anti-human IgG (Fc) antibody was immobilized onto four channels of a CM5 chip using amine coupling chemistry. 200 -300 RU of purified Cripto-1-Fc, Cryptic-Fc, ActRIIA-Fc, ActRIIB-Fc, BMPRII-Fc, ALK3-Fc, or ALK4-Fc were captured on the experimental channels. A reference channel was monitored to account for nonspecific binding, drift, and bulk shifts. To determine ligandbinding specificity, 80 nM of each ligand (see ligands above) was injected over captured Cripto-1 or Cryptic. For analysis of Cripto-1/Cryptic binding to receptors, Fc-free forms at concentrations up to 24 M were injected over captured receptors. For ligand binding kinetics, a concentration series of interacting ligands (BMP-4, Activin B, or GDF-3) was injected over captured Cripto-1 or Cryptic. To determine whether Fc dimerization causes differences in ligand binding, 4000 RU of Cripto-1 was cross-linked on the experimental channel and a concentration series of BMP-4 was injected over immobilized Cripto-1. For inhibition analysis, BMP-4 or Activin B at one concentration preincubated with various concentrations of Fcfree Cripto-1 or Cryptic was injected over captured receptors.
To determine whether the presence of a ligand affects the interaction between Cripto-1 and receptors, BMP-4 or Nodal at one concentration were preincubated with Fc-free Cripto-1 or Alk4 and injected over captured receptors. For deglycosylation experiments, Cripto-1 constructs were treated with PNGase F and Sialidase and captured on the sensor chip. SDS-PAGE was used to evaluate the glycosylation status. Deglycosylation enzymes were removed using a metal affinity column. All experiments were carried out at 25°C. HBS-EPS buffer (0.01 M HEPES, 0.5 M NaCl, 3 mM EDTA, 0.005% (v/v) Tween 20, pH 7.4) containing 0.1% BSA (Sigma) was used as running buffer at a flow rate of 50 l/min. Nodal containing samples were kept without BSA, as it causes rapid inactivation. After each binding cycle, the antibody surface was regenerated to baseline. Sensorgrams were analyzed by double referencing. To obtain kinetic rate constants, the processed data were fitted to 1:1 "two-state reaction model" using BiaEvaluation software. The equilibrium binding constant K d was determined by calculating the ratio of binding rate constants k d /k a . Results are summarized in Table  1 . For Cripto-1⅐ALK4 binding we used Biaevaluation and GraphPad Prism version 6.0h. We obtained best-fit curves by nonlinear curve fitting using a "one-site total binding" model. We determined B max , K d , and nonspecific (NS) binding contributions. For competition experiments, we obtained a best-fit inhibition curve using a non-linear regression algorithm for log(antagonist) versus normalized response model (37) .
Cross-linking-Approximately 4 g of protein samples were cross-linked with 0.01 or 0.02% glutaraldehyde for 20 min at room temperature. Native cross-linking reactions were performed in PBS. The cross-linking reaction was quenched with Tris buffer at pH 8 (final concentration: 200 mM). Samples were analyzed by 12% SDS-PAGE under reducing conditions.
Reporter Assays-For standard reporter assays, ϳ10,000 HepG2 cells/well in complete medium (Eagle's minimum essential medium (DMEM) supplemented with 10% FBS and 1% penicillin/streptomycin) were seeded in a 96-well plate and grown overnight. Each well was transfected with 0.25 l of Lipofectamine 2000, 200 ng of the SMAD1/5/8 responsive reporter plasmid pGL3 (luc2P/BRE) or the SMAD3 responsive reporter plasmid pGL4.48 (luc2P/SBE), and 2 ng of the (Luc2P/ hRluc/TK) vector (control luciferase reporter plasmid, Promega). Transfection medium was removed the following day, and replaced with assay medium (serum free DMEM ϩ 0.01% BSA) containing BMP-4, Activin B, Cripto-1-Fc, Cryptic-Fc, and/or ActRIIA-Fc. Assay medium was preincubated at 37°C for 1 h before adding to cells. For Cripto-1 overexpression studies, ϳ10,000 HepG2 cells/well were seeded in a 96-well plate and grown overnight. Each well was transfected with 0.4 l of Lipofectamine 2000, 100 ng of human TDGF-1 natural ORF mammalian expression plasmid (Sino Biological, HG10908-UT), or 100 ng of empty pCMV control vector, 100 ng of the SMAD1/5/8 responsive reporter plasmid, and 1 ng of the control reporter plasmid. Transfection medium was removed the following day, and replaced with assay medium containing a concentration series of BMP-4, BMP-2, and/or Cripto-1-Fc. Assay medium was preincubated at 37°C for 1 h before adding to cells. For Cripto-1 knockdown assays, ϳ10,000 NT2/D1 cells in complete medium were seeded in each well of a 96-well plate and grown overnight. Each well was transfected with 0.3 l of Lipofectamine 3000, 100 ng of TDGF1 shRNA (5Ј-CCGGA-CAGCACAGTAAGGAGCTAAACTCGAGTTTAGCTCCT-TACTGTGCTGTTTTTT-3Ј) (Sigma, SHCLNG-NM-003212) or scrambled shRNA control vector, 100 ng of the SMAD1/5/8 responsive reporter plasmid, and 1 ng of the control reporter plasmid. Transfection medium was removed the following day, and replaced with assay medium. After 48 h, assay medium was replaced with fresh assay medium containing 0, 1, and 10 nM BMP-4.
After addition of assay medium, cells were incubated for 16 h at 37°C, luciferase activity was detected using a homemade dual-glow luciferase assay (44) . Luminescence was determined using a FluoStar Omega plate reader. Relative luciferase units were calculated by dividing firefly luciferase units with Renilla luciferase units. To obtain IC 50 values, we used a non-linear regression algorithm for log(antagonist) versus normalized response model (GraphPad). Data are expressed as mean of four independent measurements. Error bars correspond to S.E. of four biological replicates.
Immunoblotting-Cell lysates were prepared in RIPA buffer as previously described (50) . Protein concentration of total cell lysate was determined with the Bradford assay. 10 g of cell lysate were loaded on 12% SDS-polyacrylamide gels under reducing conditions. Western blot analysis was performed with antibodies specific for Cripto-1 (Abcam, ab108391) and ␤-actin (Cell Signaling, 8H10D10). WesternBright Sirius HRP substrate was used for detection (Advansta, K-12043-D10). Western blots were visualized by exposing the membrane to autoradiography film.
XEN Cell Differentiation Assays-In vitro differentiation followed previously described protocols (39, 40, 66) . Briefly, cell culture dishes were treated with poly-L-ornithine (Sigma) for 30 min at room temperature, followed by Laminin (Sigma) at a final concentration of 0.15 g/cm 2 . XEN cells were plated at a density of ϳ20,000 cells/well of a 24-well dish in N2B27 medium (50% DMEM/F-12 (Invitrogen) ϩ 50% neural basal medium (Invitrogen) ϩ N2 medium (Invitrogen, ϫ100) ϩ B27 (Invitrogen, ϫ50) ϩ penicillin/streptomycin (10,000 units each), ␤-mercaptoethanol (55 mM)), and cultured overnight at 37°C and 5% CO 2 . On days 2, 4, and 6, the culture medium was replaced with fresh N2B27, N2B27 ϩ 50 ng/l of BMP-4, N2B27 ϩ 50 ng/l of BMP-4 ϩ 50 g/ml of Cripto-1-Fc, or N2B27 ϩ 50 g/ml of Cripto-1-Fc. After 6 days, cells in each treatment were imaged and harvested for mRNA analysis. RNA was harvested with TRIzol (Invitrogen), and reverse transcribed using Qiagen QuantiTect Reverse Transcription Kit. The resulting cDNA was analyzed on a Lightcycler 480 (Roche Applied Science) as described (66, 67) .
Statistics-Cell-based assays were performed in quadruplicates and were repeated at least two different times. Statistical significance was determined using a two-tailed t test. p values Ͻ0.05 were considered statistically significant. 
